NTRK Fusions in Paediatric Cancers

WEBINAR: NTRK Fusions in Paediatric Cancers

Thursday, 5 March 2020
20:00-21:00 (Singapore UTC+8)


Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusions are an emerging category of genetic alterations that occur in a broad range of both paediatric and adult cancers. Identification of NTRK gene fusions is important because of recent FDA approval of tumour-agnostic targeted therapeutics against cancers with such gene alterations.

In this webinar, pathologist Adj Assoc Prof Kenneth Chang discusses the challenges and approaches of diagnosing such cancers using both conventional and molecular pathology techniques in the clinical setting. Paediatric oncologist Dr Prasad Iyer describes a patient care journey. Adult oncologist and researcher Assoc Prof Daniel Tan provides an update on local clinical trials of NTRK inhibitors. The Webinar is moderated by paediatric oncologist Dr Soh Shui Yen

This webinar is supported with an educational grant from Bayer South East Asia.



NTRK play  


Adj Assoc Prof Kenneth Chang
Head & Senior Consultant
Pathology & Laboratory Medicine
KK Women’s and Children’s Hospital

Dr Kenneth Chang is Senior Consultant Paediatric Pathologist and Head of Department, Department of Pathology and Laboratory Medicine at KK Women’s and Children’s Hospital in Singapore. He is Adjunct Associate Professor at Duke-NUS Medical School, and Academic Vice-Chair for Clinical Service Transformation in the SingHealth Duke-NUS Pathology Academic Clinical Programme. He is Director of the SingHealth Tissue Repository and Advanced Molecular Pathology Laboratory. He is Principal Investigator in the VIVA-KKH Paediatric Brain and Solid Tumours Programme. He completed a 2-year clinical fellowship in paediatric pathology in the Hospital for Sick Children in Toronto, Canada and University of Toronto from 2007 to 2009. Currently, he is also a Council Member in the International Paediatric Pathology Association and plays a role in outreach to paediatric pathologists in the Asia-Pacific region.



prasad iyer

Dr Prasad Iyer
Paediatric Haematology / Oncology Service
KK Women’s and Children’s Hospital

Dr Prasad Iyer is a Consultant from the Children’s Cancer Centre, at KK Women's and Children's Hospital, Singapore. After completing his post-graduate training in Paediatrics in India he went to the United Kingdom and completed his advanced specialist training in Manchester. He complemented this training with a further four years in paediatric/adolescent oncology and haematopoietic stem cell transplantation at The Great North Children’s Hospital (Royal Victoria Infirmary) Newcastle (UK) and was conferred the Fellowship of the Royal College of Paediatrics and Child Health. He has a keen interest in precision medicine, cellular therapy and bone marrow transplantation. He is a teaching faculty in all three medical schools in Singapore and has an active interest in clinical research.


Dr Daniel Tan

Assoc Prof Daniel Tan
Senior Consultant
National Cancer Centre

Dr Daniel Tan is a Senior Consultant Medical Oncologist at Division of Medical Oncology, National Cancer Centre, an Associate Professor at Duke-NUS Medical School, and a Senior Clinician-Scientist at Genome Institute of Singapore.  He has a sub-specialty interest in thoracic, head and neck oncology, and drug development.   He is currently Director of the Experimental Cancer Therapeutics Unit – running 35-40 early phase studies (including First-in-Human trials), as well as Principal Investigator of the Cancer Therapeutics Research Laboratory – focused on unraveling mechanisms of resistance to targeted therapeutics through disease modeling in representative preclinical models.

He received undergraduate training at St Bartholomew’s and Royal London Hospitals, intercalated a BSc in tumor biology from University College London, and undertook a postgraduate fellowship in drug development at the Royal Marsden Hospital.  He completed his PhD in Cancer Biology from Cancer Science Institute, National University of Singapore and obtained a Clinician-Scientist Award from the National Medical Research Council of Singapore.




prasad iyer


Dr Soh Shui Yen
Head and Senior Consultant
Paediatric Haematology / Oncology Service
KK Women’s and Children’s Hospital

Dr Soh Shui-Yen is the Head and Senior Consultant from the Paediatric Haematology/Oncology Service of KK Women’s and Children’s Hospital (KKH) in Singapore. Dr Soh graduated from the Faculty of Medicine, National University of Singapore (NUS). She received her Paediatric Medicine training in Singapore and also completed 1 year of Paediatric Oncology clinical fellowship at the Hospital of Sick Children in Toronto, Canada. Her academic interests are in paediatric brain and solid tumours, as well as in cellular and immunotherapies in cancer. She is currently the Chair of the Paediatric Oncology Group Singapore and a steering committee member of the VIVA-KKH Paediatric Brain and Solid Tumour Programme. She also holds teaching appointments with the NUS Yong Loo Lin School of Medicine, the Duke-NUS Graduate School of Medicine, the National Technological University (NTU) – Lee Kong Chian (LKC) School of Medicine and the SingHealth Paediatrics Residency Programme.




This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by your country’s health authority. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.